QCA First Fund II Portfolio Companies
AssureRx,
LLC, is a personalized medicine company dedicated to helping
physicians determine the right drug at the right dose for
individual patients suffering from a range of medical
conditions. The company was founded in June 2006 to license and
commercialize the industry-leading personalized medicine
technology of Cincinnati Children’s Hospital and the Mayo
Clinic.
QCA First Fund II joined with Blue Chip Validation Fund and Cincinnati Children's Hospital to provide seed round funding to launch the company and begin the process of commercializing the product.
The Perseverance Group plans to deliver a new subscription-based
solution to help colleges and universities retain students.
The company will deliver secure online mentoring programs
connecting alumni to students to keep both constituencies
engaged with the institution. This will generate higher
retention rates resulting in increased tuition revenue and a new
way for alumni to “give back”.
QCA First Fund II has provided convertible debt financing to locate potential beta sites and to begin to develop the product. Follow-on funding has been provided by QCA members.
Minimally
Invasive Devices (MID) Inc. is a medical device company that
develops novel disposable instruments which allow experienced
surgeons to perform Minimally Invasive Surgery more quickly and
safely, and also make it practical for less-experienced surgeons
to perform the procedures as well. The initial product to be
developed is Clear-Vu, an after-market attachable device to
eliminate bothersome fogging and cleaning of the laparoscope
during surgery.
Teaming with OTAF and NCT Ventures in Columbus, as well as a number of individual investors, the QCA First Fund II has provided equity funding to complete the development of the first product line.
Alta
Financial Technologies uses financial rewards solutions to build
loyalty in philanthropic individuals of all ages, incomes, and
social status. The company enables the general public to
make online donations to their favorite nonprofits, receive a
tax deduction, and earn lifetime loyalty rewards. Financial
loyalty solutions are built around the patent pending
combination of charitable remainder mutual funds mechanisms
blended with the latest software transactional and internet
communication technologies.
QCA First Fund II has provided convertible debt financing so the company may begin marketing the product.
Akebia Therapeutics is a start-up pharmaceutical company which
has licensed select, high-quality drug development programs and
assets from P&G. The company’s focus is on clinical development
of novel compounds targeted for treatment of anemia and
ischemia-related disorders. One of the primary ischemia-related
products will be for treatment of peripheral artery disease
(PAD).
QCA First Fund has joined a consortium of lenders including Triathalon Medical Ventures, Blue Chip Validation Fund, and Sigvion Capital to provide start-up capital to the company.
Xanthostat
Diagnostics has developed and is pursuing FDA 510k approval for
its initial product, which will measure bilirubin and hemoglobin
concentrations in spinal fluid. This test will be an important
advancement in the early and accurate diagnosis of subarachnoid
hemorrhage. The company is using technology developed at and
licensed from the University of Cincinnati.
A convertible loan was made to the company by the Fund to provide operating capital until the product receives FDA approval.
HOPS
Technology Incorporated (HTI) is a provider of advanced
solutions that help companies manage their business and projects
with the highest level of speed, quality, and people
productivity.
Through the implementation and use of the “Hands On Proactive Software” (HOPS®) patent-pending methodologies and software products, business owners are able to quickly and easily manage projects, share critical information with all their constituents, and achieve high performance results.
QCA First Fund II has provided a convertible loan to the company to enable it to begin marketing its software.
Duffix
Golf Products has introduced it's first product--a swing trainer
which attaches to any golf club and allows a golfer to correct
problems with his/her swing. The attachment adds an
off-center weight which tends to torque the club in the proper
direction. By training with the device, the golfer can
learn what it feels like to hit the ball properly, gaining
important muscle memory. The Duffix swing trainer will be
marketed to individuals primarily through teaching
professionals.
A convertible loan was made to the company by the Fund to enable it to build initial inventory and begin the sales process.
iStatus
is a technology company which sells tools to B2B distributors
which allow them to quickly and easily create customized web
store fronts for each of their customers. Only the
appropriate subset of products is displayed and unique business
rules can be incorporated to allow a distributor to meet the
exact needs of each customer. These tools allow the site
creation process to be reduced from days or weeks to minutes.
QCA First Fund II combined with the Blue Chip Validation Fund, CincyTech, and individual investors to provide the start-up funding for iStatus.
AssureRx,
LLC, is a personalized medicine company dedicated to helping
physicians determine the right drug at the right dose for
individual patients suffering from a range of medical
conditions. The company was founded in June 2006 to license and
commercialize the industry-leading personalized medicine
technology of Cincinnati Children’s Hospital and the Mayo
Clinic.QCA First Fund II joined with Blue Chip Validation Fund and Cincinnati Children's Hospital to provide seed round funding to launch the company and begin the process of commercializing the product.
The Perseverance Group plans to deliver a new subscription-based
solution to help colleges and universities retain students.
The company will deliver secure online mentoring programs
connecting alumni to students to keep both constituencies
engaged with the institution. This will generate higher
retention rates resulting in increased tuition revenue and a new
way for alumni to “give back”.QCA First Fund II has provided convertible debt financing to locate potential beta sites and to begin to develop the product. Follow-on funding has been provided by QCA members.
Minimally
Invasive Devices (MID) Inc. is a medical device company that
develops novel disposable instruments which allow experienced
surgeons to perform Minimally Invasive Surgery more quickly and
safely, and also make it practical for less-experienced surgeons
to perform the procedures as well. The initial product to be
developed is Clear-Vu, an after-market attachable device to
eliminate bothersome fogging and cleaning of the laparoscope
during surgery.Teaming with OTAF and NCT Ventures in Columbus, as well as a number of individual investors, the QCA First Fund II has provided equity funding to complete the development of the first product line.
Alta
Financial Technologies uses financial rewards solutions to build
loyalty in philanthropic individuals of all ages, incomes, and
social status. The company enables the general public to
make online donations to their favorite nonprofits, receive a
tax deduction, and earn lifetime loyalty rewards. Financial
loyalty solutions are built around the patent pending
combination of charitable remainder mutual funds mechanisms
blended with the latest software transactional and internet
communication technologies.QCA First Fund II has provided convertible debt financing so the company may begin marketing the product.
Akebia Therapeutics is a start-up pharmaceutical company which
has licensed select, high-quality drug development programs and
assets from P&G. The company’s focus is on clinical development
of novel compounds targeted for treatment of anemia and
ischemia-related disorders. One of the primary ischemia-related
products will be for treatment of peripheral artery disease
(PAD).QCA First Fund has joined a consortium of lenders including Triathalon Medical Ventures, Blue Chip Validation Fund, and Sigvion Capital to provide start-up capital to the company.
Xanthostat
Diagnostics has developed and is pursuing FDA 510k approval for
its initial product, which will measure bilirubin and hemoglobin
concentrations in spinal fluid. This test will be an important
advancement in the early and accurate diagnosis of subarachnoid
hemorrhage. The company is using technology developed at and
licensed from the University of Cincinnati.A convertible loan was made to the company by the Fund to provide operating capital until the product receives FDA approval.
HOPS
Technology Incorporated (HTI) is a provider of advanced
solutions that help companies manage their business and projects
with the highest level of speed, quality, and people
productivity. Through the implementation and use of the “Hands On Proactive Software” (HOPS®) patent-pending methodologies and software products, business owners are able to quickly and easily manage projects, share critical information with all their constituents, and achieve high performance results.
QCA First Fund II has provided a convertible loan to the company to enable it to begin marketing its software.
Duffix
Golf Products has introduced it's first product--a swing trainer
which attaches to any golf club and allows a golfer to correct
problems with his/her swing. The attachment adds an
off-center weight which tends to torque the club in the proper
direction. By training with the device, the golfer can
learn what it feels like to hit the ball properly, gaining
important muscle memory. The Duffix swing trainer will be
marketed to individuals primarily through teaching
professionals.A convertible loan was made to the company by the Fund to enable it to build initial inventory and begin the sales process.
iStatus
is a technology company which sells tools to B2B distributors
which allow them to quickly and easily create customized web
store fronts for each of their customers. Only the
appropriate subset of products is displayed and unique business
rules can be incorporated to allow a distributor to meet the
exact needs of each customer. These tools allow the site
creation process to be reduced from days or weeks to minutes.QCA First Fund II combined with the Blue Chip Validation Fund, CincyTech, and individual investors to provide the start-up funding for iStatus.
